Search - tctmd.com

Displaying 341 - 360 of 1522

Sort: Relevancy | Date

Presentation TCT 2022

Influential Trials in High-Risk PCI: Shaping the Future of Ischemic Heart Failure Therapy

Presenter: Jonathan Hill

September 18, 2022

Presentation TCT 2022

The Future of Sirolimus Coated Balloons: a look at the design of IDE clinical trials

Presenter: Azeem Latib

September 18, 2022

Presentation TCT 2022

Sirolimus Coated Balloon in real life complex settings: Case Presentations with long term FU and positive remodelling

Presenter: Sandeep Basavarajaiah

September 18, 2022

Presentation TCT 2022

Sirolimus-coated balloon: from EASTBOURNE, the Largest DCB study ever, to the next step, TRANSFORM 2 RCT

Presenter: Bernardo Cortese

September 18, 2022

Presentation TCT 2022

DCB in CAD: understanding the existing and new indications

Presenter: Antonio Colombo

September 18, 2022

Presentation TCT 2022

Sirolimus Coated Balloon with Nanolute Technology: Pre-clinical Insights and Rationale

Presenter: Aloke Finn

September 18, 2022

Presentation TCT 2022

Introduction & Session Objectives

Presenter: Martin Leon

September 18, 2022

Presentation TCT 2022

TCT 131: Impact of Scoring Balloons on Drug Absorption Prior to Drug-coated Balloon Deployment- a Cadaver-based Study

Presenter: John Shulze

September 18, 2022

Presentation TCT 2022

TCT 177: Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: Final 2-Year Results from the Disrupt CAD III Study

Presenter: Matthew Price

September 18, 2022

Presentation TCT 2022

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

Presenter: Davide Capodanno

September 18, 2022

Presentation TCT 2022

Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial

Presenter: Christos Rammos

September 17, 2022

Presentation TCT 2022

Case-Based Presentation: Sex-Specific Considerations of Physiologic Assessment of CAD in the Cath Lab

Presenter: Rasha Al-Lamee

September 17, 2022

Presentation TCT 2022

Keynote Speech: Diagnosis and Treatment of CAD in Women – The Role of Social Determinant of Health

Presenter: Clyde Yancy

September 17, 2022

Presentation TCT 2022

Management of Coronary Artery Disease in CLTI? Is That the Ticket?

Presenter: Christopher Zarins

September 17, 2022

Presentation TCT 2022

Case #1: Multivessel Coronary Artery Disease

Presenter: Aakriti Gupta

September 17, 2022

Presentation ESC 2022

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Presenter: John H. Alexander

August 28, 2022

Presentation Interventional Complications 2022

Orbital Atherectomy Complications: Avoiding Perforations and the More Arcane

Presenter: Allen Jeremias

July 16, 2022

Presentation TVT 2022

Management of CAD in TAVR: Treat Before, During, After, OR Not at All (COMPLETE TAVR Updates)

Presenter: David Wood

June 09, 2022

Presentation Fellows 2022

The role of coronary physiology in the management of CAD – Evidence base and guidelines.

Presenter: Ajay Kirtane

May 07, 2022

Presentation ARCH 2022

Update on Pharmacology in the Cath Lab

Presenter: James B. Hermiller

April 23, 2022

Advertisement

Influential Trials in High-Risk PCI: Shaping the Future of Ischemic Heart Failure Therapy

The Future of Sirolimus Coated Balloons: a look at the design of IDE clinical trials

Sirolimus Coated Balloon in real life complex settings: Case Presentations with long term FU and positive remodelling

Sirolimus-coated balloon: from EASTBOURNE, the Largest DCB study ever, to the next step, TRANSFORM 2 RCT

DCB in CAD: understanding the existing and new indications

Sirolimus Coated Balloon with Nanolute Technology: Pre-clinical Insights and Rationale

Introduction & Session Objectives

TCT 131: Impact of Scoring Balloons on Drug Absorption Prior to Drug-coated Balloon Deployment- a Cadaver-based Study

TCT 177: Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: Final 2-Year Results from the Disrupt CAD III Study

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial

Case-Based Presentation: Sex-Specific Considerations of Physiologic Assessment of CAD in the Cath Lab

Keynote Speech: Diagnosis and Treatment of CAD in Women – The Role of Social Determinant of Health

Management of Coronary Artery Disease in CLTI? Is That the Ticket?

Case #1: Multivessel Coronary Artery Disease

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Orbital Atherectomy Complications: Avoiding Perforations and the More Arcane

Management of CAD in TAVR: Treat Before, During, After, OR Not at All (COMPLETE TAVR Updates)

The role of coronary physiology in the management of CAD – Evidence base and guidelines.

Update on Pharmacology in the Cath Lab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content